Dec 17 (Reuters) - Eli Lilly and Co on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.
The drugmaker said it expects earnings per share between $6.70 and $6.80 on an adjusted basis for 2020. Analysts were expecting a profit of $6.63 per share, according to Refinitiv IBES data. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
Our Standards: The Thomson Reuters Trust Principles.